VTV
Another analyst says “still like it”
BTIG didn’t blink. The firm reiterated a Buy on vTv Therapeutics and kept its $49 price target, which is a polite Wall Street way of saying, “we still think this one has room to run.” With shares around $37.20 in the piece, that target pointed to about 32% upside.
Why the bulls are hanging around
The call wasn’t just about one drug doing the heavy lifting. BTIG pointed to a few things investors tend to care about when the biotech roller coaster gets bumpy:
- cadisegliatin: the lead asset for type 1 diabetes, with first-in-class appeal and Breakthrough Therapy Designation
- CATT1 Phase 3 enrollment: expected to wrap in Q3 2026, with topline data roughly seven to eight months later
- Balance sheet strength: the company says it’s fully financed through the readout, which is the kind of sentence that helps keep the panic button untouched
Not just one-shot biotech vibes
BTIG also liked that vTv’s broader small-molecule pipeline gives it some optionality beyond the lead program. That matters because biotech investors hate putting all their hopes in one petri dish. The firm also flagged the recent HPP737 license amendment with Newsoara Biopharma as a sign the company can turn pipeline assets into cash and validation.
The investor takeaway
This isn’t a fresh clinical readout or a giant deal, so it’s not the kind of headline that changes the world in five minutes. But rating reiterations can still matter when they reinforce the market’s narrative: vTv Therapeutics remains a pipeline-driven story with enough financial runway to keep advancing its lead program.
Big picture: if you’re watching biotech names for upside tied to milestone progress, this is another small but meaningful nudge that the Street still thinks vTv’s story has legs.